OBJECTIVES: Reduced caveolin-1 levels in lung fibroblasts from patients with scleroderma and the lungs of bleomycin-treated mice promote collagen overexpression and lung fibrosis. This study was undertaken to determine whether caveolin-1 is deficient in leucocytes from bleomycin-treated mice and patients with scleroderma and to examine the consequences of this deficiency and its reversal. METHODS: Mice or cells received the caveolin-1 scaffolding domain (CSD) peptide to reverse the pathological effects of reduced caveolin-1 expression. In bleomycin-treated mice, the levels of caveolin-1 in leucocytes and the effect of CSD peptide on leucocyte accumulation in lung tissue were examined. To validate the results in human disease and to identify caveolin-1-regulated molecular mechanisms, monocytes and neutrophils were isolated from patients with scleroderma and control subjects and caveolin-1, extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK), p38, CXC chemokine receptor 4 (CXCR4) and matrix metalloproteinase 9 (MMP-9) expression/activation were evaluated. These parameters were also studied in monocytes treated with cytokines or CSD peptide. RESULTS: Leucocyte caveolin-1 is important in lung fibrosis. In bleomycin-treated mice, caveolin-1 expression was diminished in monocytes and CSD peptide inhibited leucocyte recruitment into the lungs. These observations are relevant to human disease. Monocytes and neutrophils from patients with scleroderma contained less caveolin-1 and more activated ERK, JNK and p38 than those from control subjects. Treatment with CSD peptide reversed ERK, JNK and p38 hyperactivation. Scleroderma monocytes also overexpressed CXCR4 and MMP-9, which was inhibited by the CSD peptide. Cytokine treatment of normal monocytes caused adoption of the scleroderma phenotype (low caveolin-1, high CXCR4 and MMP-9 and signalling molecule hyperactivation). CONCLUSIONS: Caveolin-1 downregulation in leucocytes contributes to fibrotic lung disease, highlighting caveolin-1 as a promising therapeutic target in scleroderma.
OBJECTIVES: Reduced caveolin-1 levels in lung fibroblasts from patients with scleroderma and the lungs of bleomycin-treated mice promote collagen overexpression and lung fibrosis. This study was undertaken to determine whether caveolin-1 is deficient in leucocytes from bleomycin-treated mice and patients with scleroderma and to examine the consequences of this deficiency and its reversal. METHODS:Mice or cells received the caveolin-1 scaffolding domain (CSD) peptide to reverse the pathological effects of reduced caveolin-1 expression. In bleomycin-treated mice, the levels of caveolin-1 in leucocytes and the effect of CSD peptide on leucocyte accumulation in lung tissue were examined. To validate the results in human disease and to identify caveolin-1-regulated molecular mechanisms, monocytes and neutrophils were isolated from patients with scleroderma and control subjects and caveolin-1, extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK), p38, CXC chemokine receptor 4 (CXCR4) and matrix metalloproteinase 9 (MMP-9) expression/activation were evaluated. These parameters were also studied in monocytes treated with cytokines or CSD peptide. RESULTS: Leucocyte caveolin-1 is important in lung fibrosis. In bleomycin-treated mice, caveolin-1 expression was diminished in monocytes and CSD peptide inhibited leucocyte recruitment into the lungs. These observations are relevant to human disease. Monocytes and neutrophils from patients with scleroderma contained less caveolin-1 and more activated ERK, JNK and p38 than those from control subjects. Treatment with CSD peptide reversed ERK, JNK and p38 hyperactivation. Scleroderma monocytes also overexpressed CXCR4 and MMP-9, which was inhibited by the CSD peptide. Cytokine treatment of normal monocytes caused adoption of the scleroderma phenotype (low caveolin-1, high CXCR4 and MMP-9 and signalling molecule hyperactivation). CONCLUSIONS:Caveolin-1 downregulation in leucocytes contributes to fibrotic lung disease, highlighting caveolin-1 as a promising therapeutic target in scleroderma.
Authors: Bethany B Moore; Jill E Kolodsick; Victor J Thannickal; Kenneth Cooke; Thomas A Moore; Cory Hogaboam; Carol A Wilke; Galen B Toews Journal: Am J Pathol Date: 2005-03 Impact factor: 4.307
Authors: Pascal N Bernatchez; Philip M Bauer; Jun Yu; Jay S Prendergast; Pingnian He; William C Sessa Journal: Proc Natl Acad Sci U S A Date: 2005-01-06 Impact factor: 11.205
Authors: M R Hussein; H I Hassan; E R M Hofny; M Elkholy; N A Fatehy; A E A Abd Elmoniem; A M Ezz El-Din; O A Afifi; H G Rashed Journal: J Clin Pathol Date: 2005-02 Impact factor: 3.411
Authors: Elena Tourkina; Pal Gooz; Jaspreet Pannu; Michael Bonner; Dimitri Scholz; Sharon Hacker; Richard M Silver; Maria Trojanowska; Stanley Hoffman Journal: J Biol Chem Date: 2005-02-03 Impact factor: 5.157
Authors: Elena Tourkina; Mathieu Richard; Pal Gööz; Michael Bonner; Jaspreet Pannu; Russell Harley; Pascal N Bernatchez; William C Sessa; Richard M Silver; Stanley Hoffman Journal: Am J Physiol Lung Cell Mol Physiol Date: 2008-01-18 Impact factor: 5.464
Authors: Roderick J Phillips; Marie D Burdick; Kurt Hong; Marin A Lutz; Lynne A Murray; Ying Ying Xue; John A Belperio; Michael P Keane; Robert M Strieter Journal: J Clin Invest Date: 2004-08 Impact factor: 14.808
Authors: Nikolaos A Maniatis; Vasily Shinin; Dean E Schraufnagel; Shigenori Okada; Stephen M Vogel; Asrar B Malik; Richard D Minshall Journal: Am J Physiol Lung Cell Mol Physiol Date: 2008-01-11 Impact factor: 5.464
Authors: Yang Jin; Seon-Jin Lee; Richard D Minshall; Augustine M K Choi Journal: Am J Physiol Lung Cell Mol Physiol Date: 2010-11-19 Impact factor: 5.464
Authors: Rebecca Lee; Charles Reese; Michael Bonner; Elena Tourkina; Zoltan Hajdu; Ellen C Riemer; Richard M Silver; Richard P Visconti; Stanley Hoffman Journal: Am J Physiol Lung Cell Mol Physiol Date: 2014-02-28 Impact factor: 5.464
Authors: Charles Reese; Beth Perry; Jonathan Heywood; Michael Bonner; Richard P Visconti; Rebecca Lee; Corey M Hatfield; Richard M Silver; Stanley Hoffman; Elena Tourkina Journal: Arthritis Rheumatol Date: 2014-07 Impact factor: 10.995
Authors: S N Bains; E Tourkina; C Atkinson; K Joseph; B Tholanikunnel; H W Chu; E C Riemer; R Martin; S Hoffman Journal: Allergy Date: 2012-09-25 Impact factor: 13.146
Authors: Richard M Silver; Galina Bogatkevich; Elena Tourkina; Paul J Nietert; Stanley Hoffman Journal: Curr Opin Rheumatol Date: 2012-11 Impact factor: 5.006